Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine

References

• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13(12):904–927.
   PubMed Web of Science ®Google Scholar
• Hynes RO, Naba A. Overview of the matrisome – an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012;4(1):a004903.
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 2010;1803(1):39–54.
   PubMed Web of Science ®Google Scholar
• Harisi R, Jeney A. Extracellular matrix as target for antitumor therapy. Onco Targets Ther. 2015;8:1387–1398.
   PubMed Web of Science ®Google Scholar
• Galliera E, Tacchini L, Corsi Romanelli MM. Matrix metalloproteinases as biomarkers of disease: updates and new insights. Clin Chem Lab Med. 2015;53(3):349–355.
   Web of Science ®Google Scholar
• Zarella BL, Cardoso CA, Pelá VT, Kato MT, Tjäderhane L, Buzalaf MA. The role of matrix metalloproteinases and cysteine-cathepsins on the progression of dentine erosion. Arch Oral Biol. 2015;60(9):1340–1345.
   PubMed Web of Science ®Google Scholar
• Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002;21(1):1–14.
   PubMed Web of Science ®Google Scholar
• Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm. 2013;2013:659282.
   PubMed Web of Science ®Google Scholar
• Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 1997;6(5):199–213.
   Web of Science ®Google Scholar
• Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002;169(5):2643–2647.
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest. 1998;78(9):1077–1087.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y. Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis. J Pathol. 2000;191(3):299–305.
   Web of Science ®Google Scholar
• Shimshoni E, Yablecovitch D, Baram L, Dotan I, Sagi I. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2015;64(3):367–372.
   Web of Science ®Google Scholar
• Duarte S, Baber J, Fujii T, Coito AJ. Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol. 2015;44-46:147–156.
   Web of Science ®Google Scholar
• Wilson D. Support for writers. Aust Vet J. 1998;76(5):331.
   Web of Science ®Google Scholar
• Gjorevski N, Nelson CM. Bidirectional extracellular matrix signaling during tissue morphogenesis. Cytokine Growth Factor Rev. 2009;20(5–6):459–465.
   Web of Science ®Google Scholar
• Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(1):26–34.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174.
   PubMed Web of Science ®Google Scholar
• Gaffney J, Solomonov I, Zehorai E, Sagi I. Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo. Matrix Biol. 2015;44-46:191–199.
   Web of Science ®Google Scholar
• Overall CM, Kleifeld O. Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6(3):227–239.
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013;34(4):2041–2051.
   PubMedGoogle Scholar
• Kuvaja P, Wurtz S&#216, Talvensaari-Mattila A, Brunner N, Pääkkö P, Turpeenniemi-Hujanen T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma – a validation study. Cancer Biomark. 2007;3(6):293–300.
   Google Scholar
• Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284(5751):67–68.
   Web of Science ®Google Scholar
• Liu H, Kato Y, Erzinger SA, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer. 2012;12:583.
   PubMedGoogle Scholar
• Okuyama N, Matsumine A, Kosugi R, Wakabayashi H, Uchida A. Matrix metalloproteinase-1 is a crucial bone metastasis factor in a human breast cancer-derived highly invasive cell line. Oncol Rep. 2008;20(6):1497–1504.
   Web of Science ®Google Scholar
• Fanjul-Fernandez M, Folgueras AR, Fueyo A, et al. Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J Biol Chem. 2013;288(20):14647–14656.
   Web of Science ®Google Scholar
• Pivetta E, Scapolan M, Pecolo M, et al. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res. 2011;13(5):R105.
   Web of Science ®Google Scholar
• Kudo Y, Iizuka S, Yoshida M, et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J Biol Chem. 2012;287(46):38716–38728.
   Web of Science ®Google Scholar
• Meierjohann S, Hufnagel A, Wende E, et al. MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Mol Cancer. 2010;9:201.
   Web of Science ®Google Scholar
• Kominsky SL, Doucet M, Thorpe M, Weber KL. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1. Clin Exp Metastasis. 2008;25(8):865–870.
   Web of Science ®Google Scholar
• Vayrynen JP, Vornanen J, Tervahartiala T, et al. Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int J Cancer. 2012;131(4):E463–E474.
   Web of Science ®Google Scholar
• Lempinen M, Lyytinen I, Nordin A, et al. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann Med. 2013;45(7):482–487.
   PubMed Web of Science ®Google Scholar
• Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008;8:77.
   PubMed Web of Science ®Google Scholar
• Hou CH, Chiang YC, Fong YC, Tang CH. WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol. 2011;81(11):1286–1295.
   Web of Science ®Google Scholar
• Łukaszewicz-Zajac M, Mroczko B, Guzińska-Ustymowicz K, et al. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci. 2013;58(2):235–243.
   Web of Science ®Google Scholar
• Wang R, Ke ZF, Wang F, et al. GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem. 2015;35(3):969–982.
   Google Scholar
• Hassona Y, Cirillo N, Heesom K, Parkinson EK, Prime SS. Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion. Br J Cancer. 2014;111(6):1230–1237.
   Web of Science ®Google Scholar
• Ito Y, Ishiguro H, Kobayashi N, et al. Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity. Prostate. 2015;75(10):1009–1019.
   Web of Science ®Google Scholar
• Wang L, Zhang ZG, Zhang RL, et al. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci. 2006;26(22):5996–6003.
   PubMed Web of Science ®Google Scholar
• Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004;10(22):7621–7628.
   PubMed Web of Science ®Google Scholar
• Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(16):9482–9487.
   PubMed Web of Science ®Google Scholar
• Shon SK, Kim A, Kim JY, Kim KI, Yang Y, Lim JS. Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun. 2009;385(2):198–203.
   Web of Science ®Google Scholar
• Li N, Wang HX, Zhang J, Ye YP, He GY. KISS-1 inhibits the proliferation and invasion of gastric carcinoma cells. World J Gastroenterol. 2012;18(15):1827–1833.
   Web of Science ®Google Scholar
• Yan C, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J Biol Chem. 2001;276(2):1164–1172.
   PubMed Web of Science ®Google Scholar
• Akter H, Park M, Kwon OS, Song EJ, Park WS, Kang MJ. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 2015;36(8):6053–6062.
   PubMedGoogle Scholar
• Zhang M, Dai C, Zhu H, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem. 2011;357(1–2):387–395.
   PubMed Web of Science ®Google Scholar
• Zhou X, Qi Y. PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation. Tumour Biol. 2014;35(9):9381–9386.
   Google Scholar
• Mehner C, Miller E, Khauv D, et al. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Mol Cancer Res. 2014;12(10):1430–1439.
   Web of Science ®Google Scholar
• Slavin S, Yeh CR, Da J, et al. Estrogen receptor alpha in cancer- associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis. 2014;35(6):1301–1309.
   Web of Science ®Google Scholar
• Koller FL, Dozier EA, Nam KT, et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab Invest. 2012;92(12):1749–1759.
   Web of Science ®Google Scholar
• Justilien V, Regala RP, Tseng IC, et al. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One. 2012;7(4):e35040.
   PubMed Web of Science ®Google Scholar
• Kwon YJ, Hurst DR, Steg AD, et al. Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERalpha negative breast cancer cell lines. Clin Exp Metastasis. 2011;28(5):437–449.
   Web of Science ®Google Scholar
• Eiró N, Fernandez-Garcia B, González LO, Vizoso FJ. Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis. Oncoimmunology. 2013;2(5):e24010.
   Web of Science ®Google Scholar
• Strand S, Vollmer P, van den Abeelen L, et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene. 2004;23(20):3732–3736.
   Web of Science ®Google Scholar
• Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999;45(2):252–258.
   Web of Science ®Google Scholar
• Fukuda A, Wang SC, Morris JP 4th, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19(4):441–455.
   PubMed Web of Science ®Google Scholar
• Chang MC, Chen CA, Chen PJ, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012;442(2):293–302.
   PubMedGoogle Scholar
• Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res. 2001;7(10):3289–3297.
   Web of Science ®Google Scholar
• Lu H, Hu L, Yu L, et al. KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. Oncogene. 2014;33(22):2909–2917.
   Web of Science ®Google Scholar
• Ager EI, Kozin SV, Kirkpatrick ND, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015;107(4):djv017.
   Google Scholar
• Tobar N, Avalos MC, Mendez N, et al. Soluble MMP-14 produced by bone marrow-derived stromal cells sheds epithelial endoglin modulating the migratory properties of human breast cancer cells. Carcinogenesis. 2014;35(8):1770–1779.
   Web of Science ®Google Scholar
• Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer. 2001;91(7):1277–1283.
   Web of Science ®Google Scholar
• Muller M, Beck IM, Gadesmann J, et al. MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Mod Pathol. 2010;23(4):511–521.
   Web of Science ®Google Scholar
• Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res. 1999;5(4):845–854.
   PubMed Web of Science ®Google Scholar
• Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999;878:236–270.
   PubMed Web of Science ®Google Scholar
• Bissett D, O’Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol. 2005;23(4):842–849.
   Web of Science ®Google Scholar
• Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19(56):6642–6650.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295(5564):2387–2392.
   PubMed Web of Science ®Google Scholar
• Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol. 1998;45(1):21–26.
   Web of Science ®Google Scholar
• Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69–75.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004;22(23):4683–4690.
   PubMed Web of Science ®Google Scholar
• Stone AL, Kroeger M, Sang QX. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). J Protein Chem. 1999;18(4):447–465.
   Google Scholar
• Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 2003;3(6):589–601.
   PubMed Web of Science ®Google Scholar
• Heljasvaara R, Nyberg P, Luostarinen J, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res. 2005;307(2):292–304.
   PubMed Web of Science ®Google Scholar
• McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289(5482):1202–1206.
   PubMed Web of Science ®Google Scholar
• Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin Microbiol Rev. 2009;22(2):224–239. Table of Contents.
   PubMed Web of Science ®Google Scholar
• Lorente L, Martin MM, Solé-Violán J, et al. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One. 2014;9(4):e94318.
   Web of Science ®Google Scholar
• O’Donoghue AJ, Knudsen GM, Beekman C, et al. Destructin-1 is a collagen-degrading endopeptidase secreted by Pseudogymnoascus destructans, the causative agent of white-nose syndrome (vol 112, pg 7478, 2015). Proc Natl Acad Sci U S A. 2015;112(24):7478–7483.
   Google Scholar
• Gao N, Kumar A, Yu FS. Matrix metalloproteinase-13 as a target for suppressing corneal ulceration caused by Pseudomonas aeruginosa infection. J Infect Dis. 2015;212(1):116–127.
   Web of Science ®Google Scholar
• Ricci S, Grandgirard D, Wenzel M, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014;14:726.
   PubMed Web of Science ®Google Scholar
• Sivula M, Hastbacka J, Kuitunen A, et al. Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis-associated coagulopathy. Acta Anaesthesiol Scand. 2015;59(2):176–184.
   Web of Science ®Google Scholar
• Marchant DJ, Bellac CL, Moraes TJ, et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat Med. 2014;20(5):493–502.
   PubMed Web of Science ®Google Scholar
• Sathyamoorthy T, Tezera LB, Walker NF, et al. Membrane type 1 matrix metalloproteinase regulates monocyte migration and collagen destruction in tuberculosis. J Immunol. 2015;195(3):882–891.
   Web of Science ®Google Scholar
• Kim MP, Gaydos CA, Wood BJ, Hardick JP, Zhang YH, Wahl LM. Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E-2-Dependent mechanism. Infect Immun. 2005;73(1):632–634.
   Web of Science ®Google Scholar
• Zuo X, Pan W, Feng T, Shi X, Dai J. Matrix metalloproteinase 3 promotes cellular anti-dengue virus response via interaction with transcription factor NF kappa B in cell nucleus. PLoS One. 2014;9(1):e84748.
   Web of Science ®Google Scholar
• Heilpern AJ, Wertheim W, He J, Perides G, Bronson RT, Hu LT. Matrix metalloproteinase 9 plays a key role in lyme arthritis but not in dissemination of Borrelia burgdorferi. Infect Immun. 2009;77(7):2643–2649.
   Web of Science ®Google Scholar
• Prato M, D’Alessandro S, Van den Steen PE, et al. Natural haemozoin modulates matrix metalloproteinases and induces morphological changes in human microvascular endothelium. Cell Microbiol. 2011;13(8):1275–1285.
   PubMed Web of Science ®Google Scholar
• Harbut MB, Velmourougane G, Dalal S, et al. Bestatin-based chemical biology strategy reveals distinct roles for malaria M1-and M17-family aminopeptidases. Proc Natl Acad Sci U S A. 2011;108(34):E526–E534.
   Web of Science ®Google Scholar
• Elkington PT, O’Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol. 2005;142(1):12–20.
   PubMed Web of Science ®Google Scholar
• Solan PD, Dunsmore KE, Denenberg AG, Odoms K, Zingarelli B, Wong HR. A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med. 2012;40(2):379–387.
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Brueckmann M, Borggrefe M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis? Crit Care. 2009;13(6):1006.
   Web of Science ®Google Scholar
• Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013;5(7):1000–1016.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Sugiura H, Koarai A, et al. TLR3 activation augments matrix metalloproteinase production through reactive nitrogen species generation in human lung fibroblasts. J Immunol. 2014;192(11):4977–4988.
   PubMed Web of Science ®Google Scholar
• Lee YH, Lai CL, Hsieh SH, Shieh CC, Huang LM, Wu-Hsieh BA. Influenza A virus induction of oxidative stress and MMP-9 is associated with severe lung pathology in a mouse model (vol 178, pg 411, 2013). Virus Res. 2014;183:123.
   Web of Science ®Google Scholar
• Bradley LM, Douglass MF, Chatterjee D, Akira S, Baaten BJ. Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling. PLoS Pathog. 2012;8(4):e1002641.
   Web of Science ®Google Scholar
• Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20(23):7312–7324.
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218.
   PubMed Web of Science ®Google Scholar
• Fallowfield JA, Kendall TJ, Iredale JP. Reversal of fibrosis: no longer a pipe dream? Clin Liver Dis. 2006;10(3):481–497, viii.
   Google Scholar
• Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem. 2007;101(4):830–839.
   Web of Science ®Google Scholar
• de Meijer VE, Sverdlov DY, Popov Y, et al. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One. 2010;5(6):e11256.
   Web of Science ®Google Scholar
• Mannino DM, Kiriz VA. Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis. 2006;1(3):219–233.
   PubMedGoogle Scholar
• Lagente V, Le Quement C, Boichot E. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. Expert Opin Ther Targets. 2009;13(3):287–295.
   PubMed Web of Science ®Google Scholar
• Merrilees MJ, Ching PST, Beaumont B, Hinek A, Wight TN, Black PN. Changes in elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary disease. Respir Res. 2008;9:41.
   Web of Science ®Google Scholar
• Eurlings IMJ, Dentener MA, Cleutjens JPM, et al. Similar matrix alterations in alveolar and small airway walls of COPD patients. BMC Pulm Med. 2014;14:90.
   PubMed Web of Science ®Google Scholar
• Le Quément C, Guénon I, Gillon JY, et al. The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol. 2008;154(6):1206–1215.
   Web of Science ®Google Scholar
• Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax. 2007;62(8):706–713.
   PubMed Web of Science ®Google Scholar
• Bidan CM, Veldsink AC, Meurs H, Gosens R. Airway and extracellular matrix mechanics in COPD. Front Physiol. 2015;6:346.
   Web of Science ®Google Scholar
• Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol. 2006;21(suppl 3):S88–S91.
   Google Scholar
• Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99(6):1160–1174.
   Web of Science ®Google Scholar
• Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta. 2010;1803(1):72–94.
   PubMed Web of Science ®Google Scholar
• Hoffman A, Qadri B, Frant J, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor – synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem. 2008;51(5):1406–1414.
   Web of Science ®Google Scholar
• Dufour A, Sampson NS, Li J, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011;71(14):4977–4988.
   PubMed Web of Science ®Google Scholar
• Dufour A, Sampson NS, Zucker S, Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol. 2008;217(3):643–651.
   Web of Science ®Google Scholar
• Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012;72(9):2339–2349.
   Web of Science ®Google Scholar
• Gao M, Nguyen TT, Suckow MA, et al. Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy. Proc Natl Acad Sci U S A. 2015;112(49):15226–15231.
   Web of Science ®Google Scholar
• Suojanen J, Salo T, Koivunen E, Sorsa T, Pirilä E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther. 2009;8(24):2362–2370.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17(8):768–774.
   PubMed Web of Science ®Google Scholar
• Heikkilä P, Suojanen J, Pirilä E, et al. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer. 2006;118(9):2202–2209.
   Web of Science ®Google Scholar
• Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol. 2015;4(4–46):239–246.
   Google Scholar
• Xu X, Chen Z, Wang Y, Bonewald L, Steffensen B. Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. Biochem J. 2007;406(1):147–155.
   Google Scholar
• Higashi S, Hirose T, Takeuchi T, Miyazaki K. Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). J Biol Chem. 2013;288(13):9066–9076.
   Web of Science ®Google Scholar
• Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of beta-amyloid precursor protein-derived inhibitor. J Biol Chem. 2011;286(38):33236–33243.
   PubMed Web of Science ®Google Scholar
• Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grotzinger J, Roeb E. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells. Int J Oncol. 2007;30(4):985–992.
   Web of Science ®Google Scholar
• Roeb E, Schleinkofer K, Kernebeck T, et al. The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem. 2002;277(52):50326–50332.
   Web of Science ®Google Scholar
• Ezhilarasan R, Jadhav U, Mohanam I, Rao JS, Gujrati M, Mohanam S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer. 2009;124(2):306–315.
   Web of Science ®Google Scholar
• Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2011;31(3):528–535.
   PubMed Web of Science ®Google Scholar
• Paemen L, Martens E, Masure S, Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem. 1995;234(3):759–765.
   Google Scholar
• Marshall DC, Lyman SK, McCauley S, et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One. 2015;10(5):e0127063.
   PubMed Web of Science ®Google Scholar
• Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517–1526.
   PubMed Web of Science ®Google Scholar
• Sela-Passwell N, Kikkeri R, Dym O, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med. 2012;18(1):143–147.
   Web of Science ®Google Scholar
• Gálvez BG, Matias-Román S, Albar JP, Sánchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem. 2001;276(40):37491–37500.
   Web of Science ®Google Scholar
• Udi Y, Grossman M, Solomonov I, et al. Inhibition mechanism of membrane metalloprotease by an exosite-swiveling conformational antibody. Structure. 2015;23(1):104–115.
   Web of Science ®Google Scholar
• Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A, Itoh Y. Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of experimental inflammatory arthritis: synergy With tumor necrosis factor blockade. Arthritis Rheumatol. 2016;68(2):521–531.
   PubMed Web of Science ®Google Scholar
• Botkjaer KA, Kwok HF, Terp MG, et al. Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo. Oncotarget. Epub 2016 Feb 27.
   Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–233.
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–732.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr Opin Biotechnol. 2011;22(6):882–887.
   PubMed Web of Science ®Google Scholar
• Kulasegaram R, Giersing B, Page CJ, et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med. 2001;28(6):756–761.
   Google Scholar
• Tran PL, Vigneron JP, Pericat D, et al. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther. 2003;10(6):435–444.
   PubMed Web of Science ®Google Scholar
• Yang SW, Cody JJ, Rivera AA, et al. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin Cancer Res. 2011;17(3):538–549.
   PubMed Web of Science ®Google Scholar
• Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011;12(11):233.
   PubMed Web of Science ®Google Scholar
• Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71.
   PubMed Web of Science ®Google Scholar
• Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825(1):29–36.
   PubMed Web of Science ®Google Scholar
• Têtu B, Brisson J, Wang CS, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 2006;8(3):R28.
   PubMed Web of Science ®Google Scholar
• Shen Q, Lee ES, Pitts RL, Wu MH, Yuan SY. Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells. Mol Cancer Res. 2010;8(7):939–951.
   Web of Science ®Google Scholar
• Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991;30(33):8097–8102.
   Web of Science ®Google Scholar
• Fernandez CA, Butterfield C, Jackson G, Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003;278(42):40989–40995.
   Web of Science ®Google Scholar
• Batra J, Robinson J, Mehner C, et al. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One. 2012;7(11):e50028.
   Web of Science ®Google Scholar
• Tlatli R, Nozach H, Collet G, et al. Grafting of functional motifs onto protein scaffolds identified by PDB screening – an efficient route to design optimizable protein binders. FEBS J. 2013;280(1):139–159.
   Web of Science ®Google Scholar
• Hamze AB, Wei S, Bahudhanapati H, Kota S, Acharya KR, Brew K. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. Protein Sci. 2007;16(9):1905–1913.
   Web of Science ®Google Scholar
• Grossman M, Tworowski D, Dym O, et al. The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry. 2010;49(29):6184–6192.
   PubMed Web of Science ®Google Scholar
• Butler GS, Hutton M, Wattam BA, et al. The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem. 1999;274(29):20391–20396.
   Web of Science ®Google Scholar
• Wei S, Chen Y, Chung L, Nagase H, Brew K. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors. J Biol Chem. 2003;278(11):9831–9834.
   Web of Science ®Google Scholar
• Banta S, Dooley K, Shur O. Replacing antibodies: engineering new binding proteins. Annu Rev Biomed Eng. 2013;15:93–113.
   Web of Science ®Google Scholar
• Jones DS, Silverman AP, Cochran JR. Developing therapeutic proteins by engineering ligand-receptor interactions. Trends Biotechnol. 2008;26(9):498–505.
   Web of Science ®Google Scholar
• Bahudhanapati H, Zhang Y, Sidhu SS, Brew K. Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). J Biol Chem. 2011;286(36):31761–31770.
   Web of Science ®Google Scholar
• Sharabi O, Shirian J, Shifman JM. Predicting affinity- and specificity-enhancing mutations at protein-protein interfaces. Biochem Soc Trans. 2013;41(5):1166–1169.
   Google Scholar
• Sharabi O, Shirian J, Grossman M, Lebendiker M, Sagi I, Shifman J. Affinity- and specificity-enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPs. PLoS One. 2014;9(4):e93712.
   Web of Science ®Google Scholar
• Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009;13(3):245–255.
   PubMed Web of Science ®Google Scholar
• Wittrup KD. Protein engineering by cell-surface display. Curr Opin Biotechnol. 2001;12(4):395–399.
   Web of Science ®Google Scholar
• Pepper LR, Cho YK, Boder ET, Shusta EV. A decade of yeast surface display technology: where are we now? Comb Chem High Throughput Screen. 2008;11(2):127–134.
   PubMed Web of Science ®Google Scholar
• Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15(6):553–557.
   PubMed Web of Science ®Google Scholar
• Boder ET, Bill JR, Nields AW, Marrack PC, Kappler JW. Yeast surface display of a noncovalent MHC class II heterodimer complexed with antigenic peptide. Biotechnol Bioeng. 2005;92(4):485–491.
   Web of Science ®Google Scholar
• Wang Z, Mathias A, Stavrou S, Neville DM Jr. A new yeast display vector permitting free scFv amino termini can augment ligand binding affinities. Protein Eng Des Sel. 2005;18(7):337–343.
   Web of Science ®Google Scholar
• Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011;1411:108–115.
   PubMed Web of Science ®Google Scholar
• Yu C, Chen WP, Wang XH. MicroRNA in osteoarthritis. J Int Med Res. 2011;39(1):1–9.
   Web of Science ®Google Scholar
• Maegdefessel L, Dalman RL, Tsao PS. Pathogenesis of abdominal aortic aneurysms: microRNAs, proteases, genetic associations. Annu Rev Med. 2014;65:49–62.
   Web of Science ®Google Scholar
• Xia H, Qi Y, Ng SS, et al. microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 2009;1269:158–165.
   PubMed Web of Science ®Google Scholar
• Gabriely G, Wurdinger T, Kesari S, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008;28(17):5369–5380.
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Custódia C, Cunha P, Pereira de Almeida L, Pedroso de Lima MC. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J Control Release. 2015;207:31–39.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Seol HJ, Park YM, et al. MicroRNA-146a suppresses metastatic activity in brain metastasis. Mol Cells. 2012;34(3):329–334.
   Web of Science ®Google Scholar
• Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol. 2012;33(6):1863–1870.
   Google Scholar
• Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19(6):1123–1130.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cai J, Wang J, Xiong C, Zhao J. MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35(12):12743–12748.
   PubMedGoogle Scholar
• He Y, Huang C, Sun X, Long XR, Lv XW, Li J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal. 2012;24(10):1923–1930.
   Web of Science ®Google Scholar
• He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95(7):1355–1359.
   PubMed Web of Science ®Google Scholar
• Wang J, Gao Y, Ma M, et al. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem Biophys. 2013;67(2):537–546.
   PubMed Web of Science ®Google Scholar
• Esteso G, Luzón E, Sarmiento E, et al. Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA. J Immunol. 2014;193(3):1344–1352.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–716.
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr. HIV-1 protease inhibitors. Clin Infect Dis. 2000;30(suppl 2):S160–S170.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Ishii M, Namkoong H, et al. Pneumococcal infection aggravates elastase-induced emphysema via MMP-12 overexpression. J Infect Dis. 2016;213(6):1018–1030.
   Web of Science ®Google Scholar